Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Diabetes Mellitus, Type 2, Diabetic Reti...
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

We plan to explore the usability of Generative AI-Chatbot for Diabetic Patient

Design

Study type: Observational Observational model: Case Only Time perspective: Cross Sectional

Interventions / Regimen

  • Behavioral: Exploring AI-Chatbot — All participants will be provided access to AI-Chatbot and will be asked to enquire their daily life problems related to diabetes. They will also be asked to review the replies of the Chatbot after their interaction.

Primary Outcomes

  • Usability of the Chatbot for diabetic patient (One time)
  • Internet Speed (One time)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-01-05
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pakistan Council of Scientific and Industrial Research
Principal Investigators:
  • Ghulam Mustafa (PRINCIPAL_INVESTIGATOR) - Pakistan Council of Scientific and Industrial Research
Contact Information
Study Contact:
Ghulam Mustafa
+923322340395
mustafabme@gmail.com
Ghulam Mustafa
mustafabme@gmail.com
CDLE, PCSIR Lbas Complex
Interventions
  • Behavioral: Exploring AI-Chatbot — All participants will be provided access to AI-Chatbot and will be asked to enquire their daily life problems related to diabetes. They will also be asked to review the replies of the Chatbot after their interaction.
Study Locations (1 sites)
CDLE, PCSIR Lbas Complex, Karachi, Sindh Pakistan
Eligibility Criteria
Inclusion Criteria: * Present physically in Pakistan * Adults (18 years or older) * Diabetic Patient Exclusion Criteria: * Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers) * Prisoners
Conditions Depressive Disorder, Major
Phase NA
Enrollment 384
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Major depressive disorder (MDD) is the most common mental disorder. It can be a huge burden not only for the person affected by it, but also for his/her whole family. The goal of this clinical trial is to test the efficacy of a family supportive intervention called psychoeducational family intervention (PFI) compared to a brief informative intervention in families with a member affected by MDD. Families will participate in one of the two interventions for a period of 6 months more or less, and they will be asked to answer some questionnaires about how much MDD impacts on their everyday life and the patient's symptoms, in order to understand whether a more structured intervention such as PFI can be useful for families in order to better deal with this complicated illness.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Other: Psychoeducational Family Intervention — Supportive intervention administered to families with a member affected by MDD
  • Other: Informative intervention — Informative intervention administered to families with a member affected by MDD

Primary Outcomes

  • Severity of depressive symptoms (At baseline, after 6-, 12- and 24 months)
  • Psychosocial functioning (At baseline, after 6-, 12- and 24 months)
  • Severity of anxiety symptoms (At baseline, after 6-, 12- and 24 months)
  • Social contacts (At baseline, after 6-, 12- and 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-27
Completion: 2026-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 384 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Campania Luigi Vanvitelli
Collaborators: Università degli Studi di Brescia, University of Bologna, University of Catanzaro, Università degli Studi 'G. d'Annunzio' Chieti e Pescara, University of Cagliari, University of Florence, Università degli Studi di Ferrara, University of Foggia, Universita degli Studi di Genova, University of Milan, University of Modena and Reggio Emilia, Università degli Studi del Piemonte Orientale Amedeo Avogadro, University of Parma, University Of Perugia, University of Pisa, Università Politecnica delle Marche, University of Roma La Sapienza, University of Rome Tor Vergata, Catholic University of the Sacred Heart, Università degli Studi di Sassari, University of Siena, Università degli studi di Trieste, Universita di Verona
Contact Information
Study Contact:
Mario Luciano, Doctor
+393490730150
mario.luciano@unicampania.it
Mario Luciano, Doctor
University of Campania L. Vanvitelli
Interventions
  • Other: Psychoeducational Family Intervention — Supportive intervention administered to families with a member affected by MDD
  • Other: Informative intervention — Informative intervention administered to families with a member affected by MDD
Study Locations (1 sites)
University of Campania L. Vanvitelli, Naples, 80138 Italy
Eligibility Criteria
Inclusion Criteria: * diagnosis of major depression, according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; * ability to provide informed consent; * presence of at least one contact per month with the psychiatric clinic for at least six months prior to recruitment; * cohabitation with at least one family member. Exclusion Criteria: * moderate or severe cognitive deficits, physical illnesses preventing the participation to the sessions or if they were hospitalization in the two months prior the enrollment
Conditions Breast Cancer, Hyperinsulinism, HER2-neg...
Phase PHASE1
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of the study is to assess metabolic plasma markers of insulin resistance in patients with early-stage HER2-negative breast cancers receiving dapagliflozin concomitant with neoadjuvant therapy.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Drug: Dapagliflozin 10mg — 10 mg tablets for oral administration daily throughout chemotherapy treatment

Primary Outcomes

  • Change in Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) (baseline, post paclitaxel treatment at week 12, and 2 weeks post neoadjuvant therapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-10-15
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yale University
Principal Investigators:
  • Maryam Lustberg, MD, MPH (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
Carl Brown
475-241-1065
carl.brown@yale.edu
Interventions
  • Drug: Dapagliflozin 10mg — 10 mg tablets for oral administration daily throughout chemotherapy treatment
Study Locations (1 sites)
Yale Cancer Center Smilow Cancer Hospital, New Haven, Connecticut 06520 United States
Eligibility Criteria
Inclusion Criteria: * Women \> 18 years of age with newly diagnosed, histologically confirmed, clinical stage I-III, HER2-negative - either ER+ or triple negative - invasive breast cancer as defined by ASCO CAP guidelines for whom neoadjuvant chemotherapy would be indicated. The following chemotherapy regimens are acceptable: 1. Weekly or dose dense paclitaxel, followed by dose dense doxorubicin plus cyclophosphamide 2. Docetaxel plus cyclophosphamide 3. Docetaxel plus carboplatin plus or minus pembrolizumab 4. Paclitaxel plus carboplatin concurrent with every 3 week pembrolizumab followed by dose dense doxorubicin plus cyclophosphamide concurrent with every 3 week pembrolizumab (KEYNOTE-522 regimen; only for participants with triple negative breast cancer) * BMI ≥ 25 kg/m2 * Hyperinsulinemia defined as HOMA-IR ≥ 2.5. * Willing and able to provide written informed consent for the trial. * Has at least one (1) physical 4-5-micron single H\&E slide from diagnostic biopsy available * Female participants of childbearing potential should have a negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. * Female participants must be 1 year post-menopausal orsurgically sterile, Women of childbearing potential who are sexually active with a non-sterilized male partner must agree to follow their chemotherapy provider's instructions for birth control. * Participants should have adequate organ function to tolerate chemotherapy, as defined by: 1. peripheral granulocyte count of \> 1,500/mm3 2. platelet count \> 100,000/mm3 3. hemoglobin \>9 g/dL 4. total bilirubin \< 1.5 x upper limit of normal (ULN) 5. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) each \< 1.5 x ULN 6. serum creatinine \< 1.5 x ULN 7. INR/PT/PTT each \< 1.5 x ULN * Able to swallow oral formulation of the study agent * Subjects should not donate blood while participating in this study, or for at least 90 days following the last dose of chemotherapy Exclusion Criteria: * Participants who underwent partial excisional biopsy or lumpectomy, segmental mastectomy or modified radical mastectomy or sentinel node biopsy and therefore cannot be assessed accurately for pathologic response, are not eligible. * Participants currently pregnant or breastfeeding. * Participants for whom any of the planned chemotherapies are contraindicated. * Participants with currently diagnosed type I or II diabetes mellitus. * Participants taking any antidiabetic medication that would affect insulin resistance or hyperinsulinemia (i.e. TZD, GLP-1RA, DPP-4i, SGLT2i, metformin) in the past one month. * Participants with history of hypersensitivity reaction to dapagliflozin. * Participants with eGFR \< 25. * History of recurrent (three or more occurrences within 12 months, or two or more occurrences within 6 months) urinary tract infections. * Currently participating in weight loss programs or weight change in the past 3 months (\> 5% current body weight) or have a history of gastrointestinal surgery. * Live vaccines within 30 days prior to the first dose of trial treatment and while participating in the trial. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, intranasal influenza, rabies, BCG, and typhoid vaccine. * Judgement by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
Conditions Chronic Thromboembolic Pulmonary Hyperte...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this patient registry is to learn about the natural history in patients with chronic thromboembolic disease (CTD) and/or chronic thromboembolic pulmonary hypertension (CTEPH). The main question\[s\] it aims to answer are: * Long-term outcome after various types of treatment, including medication, balloon pulmonary angioplasty, and pulmonary endarterectomy * Effect of treatment on patient's quality of life and exercise tolerance Participants will be followed longitudinally to assess their health outcomes and quality of life via chart review and health quality surveys.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Survey — Patients who received medical, surgical or interventional treatment for chronic thromboembolic pulmonary hypertension will be followed and given quality of life questionnaires.

Primary Outcomes

  • Total number of patients who survive (Through study completion, an average of 5 years)
  • Changes in exercise tolerance (Baseline to end of the study, an average of 5 years)
  • Changes in supplemental oxygen use severity (Baseline to end of the study, an average of 5 years)
  • Changes in New York Heart Association (NYHA) functional class (Baseline to end of the study, an average of 5 years)
  • European Quality of Life Five Dimension (EQ-5D) - Scale Score (Baseline to end of the study, an average of 5 years)
  • Changes in patients' emPHasis-10 scores (Baseline to end of the study, an average of 5 years)
  • Number of patients undergoing lung transplantation (Baseline to end of the study, an average of 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-08-01
Completion: 2028-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Francisco
Principal Investigators:
  • Miles Conrad, MD (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Miles Conrad, MD
(415) 353-1300
miles.conrad@ucsf.edu
Xiao Wu, MD
628-286-7340
xiao.wu@ucsf.edu
Miles Conrad, MD
415-353-1300
miles.conrad@ucsf.edu
University of California San Francisco
Interventions
  • Other: Survey — Patients who received medical, surgical or interventional treatment for chronic thromboembolic pulmonary hypertension will be followed and given quality of life questionnaires.
Study Locations (1 sites)
University of California San Francisco, San Francisco, California 94143 United States
Eligibility Criteria
Inclusion Criteria: * Patients referred with CTED and/or CTEPH defined as: 1. Mean pulmonary arterial pressure (mPAP) \> 20 mmHg at rest with pulmonary vascular resistance (PVR) \> 2 Wood units (WU); or if mPAP ≤ 20 mmHg or PVR ≤ 2 WU at rest, have exercise limitations from chronic thromboembolic pulmonary disease (CTEPD) without pulmonary hypertension (PH) 2. Radiologic finding of chronic thromboembolic disease, including abnormal ventilation perfusion scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram 3. Post-embolic exercise intolerance and evidence of chronic thromboembolic disease in the absence of resting pulmonary hypertension * Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH or CTEPD without PH * Age ≥ 18 years Exclusion Criteria: * Main cause of PH other than World Health Organization (WHO) group 4 (CTEPH) * Patient's refusal to participate in clinical research and/or receive intervention
Conditions Diabetes Mellitus Type 2
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The present protocol aims to understand and establish whether there is a causal link between adipose tissue metabolic remodeling and Type 2 Diabetes (T2D) remission after bariatric surgery. All participants will have a bariatric surgery, divided in 2 groups: with or without T2D.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Procedure: Bariatric surgery — Laparoscopic Sleeve Gastrectomy
  • Drug: Nicotinic Acid — Only during A1. 150mg every half hour for 6 hours. A total dose of 1800mg will be ingested.

Primary Outcomes

  • Change in white adipose tissue dietary fatty acid (DFA) trapping and partitioning (measured after liquid meal at Baseline (A0 +A1), at Day 12 (B0) and at Week 52 (C0))
  • Change in lean organ (liver, heart and muscle) DFA uptake and partitioning (measured after liquid meal at Baseline (A0 +A1), at Day 12 (B0) and at Week 52 (C0))
  • Change in liver non-esterified fatty acid (NEFA) uptake, oxidation, esterification and secretion into very low-density lipoprotein (VLDL). (measured before and after liquid meal at Baseline (A0), at Day 12 (B0) and at Week 52 (C0))
  • Change in Endogenous Glucose production and meal glucose systemic flux (measured before and after liquid meal at Baseline (A0 +A1), at Day 12 (B0) and at Week 52 (C0))
  • Change in cardiac non-esterified fatty acid (NEFA) uptake, oxidation and esterification (measured before and after liquid meal at Baseline (A0), at Day 12 (B0) and at Week 52 (C0))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-01
Completion: 2028-05-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Université de Sherbrooke
Collaborators: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval, Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Principal Investigators:
  • André Carpentier, MD (PRINCIPAL_INVESTIGATOR) - Université de Sherbrooke
Contact Information
Study Contact:
Frédérique Frisch
1-819-346-1110
frederique.frisch@usherbrooke.ca
Frederique Frisch
8193461110
frederique.frisch@usherbrooke.ca
centre de recherche du CHUS
Interventions
  • Procedure: Bariatric surgery — Laparoscopic Sleeve Gastrectomy
  • Drug: Nicotinic Acid — Only during A1. 150mg every half hour for 6 hours. A total dose of 1800mg will be ingested.
Study Locations (1 sites)
centre de recherche du CHUS, Sherbrooke, Quebec J1H 5N4 Canada
Eligibility Criteria
Inclusion Criteria: * Aged 18 to 65 * BMI 35 kg/m2 * Diagnosed T2D - according to Diabetes Canada diagnostics criteria. * Diagnosed non-T2D - according to Diabetes Canada diagnostics criteria. * Women with a negative serum pregnancy test. Exclusion Criteria: * Treatment with an oral contraceptive; * Treatment with fibrate, thiazolidinedione, insulin, or beta-blocker, drugs that affect metabolism and cannot be stopped temporarily or which have long-lasting effects; * Presence of overt cardiovascular disease, liver or renal failure or other uncontrolled medical conditions; * Any other contraindication to surgery or to temporarily suspending current medications for diabetes, lipids or hypertension; * Smoking or consumption of more than 2 alcoholic beverages per day; * Any contraindication to MRI; * A Diabetes Remission (DiaRem) score \>8 (low probability of T2D remission); * Having participated to a research study with exposure to radiation in the last two years before the start of the study; * Pregnant or breastfeeding women; * Patients weighing more than 200 kg to respect the weight and gantry limit of our MRI and PET/CT scanners. * Being allergic to eggs
Conditions Advanced Solid Tumor, High Grade Serous ...
Phase PHASE1, PHASE2
Enrollment 200
Locations 14 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: VLS-1488 — VLS-1488 tablets will be given orally.

Primary Outcomes

  • Dose Escalation: Incidence of Dose Limiting Toxicities (DLTs) in DLT-evaluable subjects (Up to 12 months)
  • Dose Escalation: Determination of the MTD of VLS-1488 (Up to 12 months)
  • Dose Escalation: Frequency of Serious Adverse Events (SAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 (Up to 12 months)
  • Dose Escalation: Frequency of Treatment-related Adverse Events (AEs) graded per NCI-CTCAE version 5.0 (Up to 12 months)
  • Dose Escalation: Frequency of Treatment-Emergent AEs (TEAEs) graded per NCI-CTCAE version 5.0 (Up to 12 months)
  • Dose Escalation: Frequency of Dose Interruptions and Permanent Treatment Discontinuations (Up to 12 months)
  • Dose Expansion: Frequency of Trigger Events (TEs) (Up to 18 months)
  • Dose Expansion: Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Up to 18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2023-10-18
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Volastra Therapeutics, Inc.
Contact Information
Study Contact:
Volastra Therapeutics, Inc.
(646) 344-1248
clinicaltrials@volastratx.com
Xiomara Menendez, RN
Xiomara.Menendez@med.usc.edu
University of Southern California
Lorraine Martinez, MD
Lorraine.Martinez@med.usc.edu
University of Southern California
Interventions
  • Drug: VLS-1488 — VLS-1488 tablets will be given orally.
Study Locations (14 sites)
University of Southern California, Los Angeles, California 90033 United States
Hoag Memorial Hospital, Newport Beach, California 92663 United States
University of Colorado Cancer Center, Aurora, Colorado 80045 United States
Yale Cancer Center, New Haven, Connecticut 06511 United States
Kellogg Cancer Center, Evanston, Illinois 60201 United States
Community Health Network, Indianapolis, Indiana 46256 United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21224 United States
University of Michigan, Ann Arbor, Michigan 48109 United States
START Midwest, Grand Rapids, Michigan 49546 United States
Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States
Eligibility Criteria
Key Inclusion Criteria: * All Parts: Age ≥ 18 years, ECOG Performance Status ≤ 1, at least 1 site of measurable disease evaluable by CT scan or MRI per RECIST 1.1, able to take oral medication without alteration * Dose Escalation: No available therapeutic options to provide clinically meaningful benefits in the following tumor types: High Grade Serous Ovarian Cancer, Squamous Non -Small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma (not EBV+), Colorectal, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction, Bladder (transitional cell), Head and Neck Squamous Cell Carcinomas (not nasopharynx, sinonasal or lip), Ovarian Carcinosarcoma, CN-high Endometrial/Uterine * Dose Expansion: Must have been previously treated with several lines of standard of care treatment specified in the protocol in the following tumor types: High Grade Serous Ovarian Cancer, Squamous Non-Small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma (not EBV+), Colorectal, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Head and Neck Squamous Cell Carcinomas (not nasopharynx, sinonasal or lip), CN-high Endometrial/Uterine Key Exclusion Criteria: * MSI-H, dMMR, POLE gene hotspot mutated, or known hypermutator phenotype * Previously received KIF18A inhibitor * Current CNS metastases or leptomeningeal disease * Cardiac parameters: MI or stroke ≤ 1 year, unstable angina/PE/DVT/CABG ≤ 6 months, NYHA Class ≥ II, LVEF \< 50% * Inability to comply with concomitant medication restrictions with respect to strong inhibitors and inducers of CYP3A, and clinical inhibitors of MDR1 (P-gp) and BCRP * Any clinically significant ascites or pleural effusions at time of enrollment, or any therapeutic paracentesis or thoracentesis within 28 days of planned first dose of study drug * Bowel obstruction or GI perforation within 6 months of planned first dose of study drug
Conditions Breast Cancer, Gastric Cancer, Gastroeso...
Phase PHASE1
Enrollment 165
Locations 13 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: IKS014 — IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.

Primary Outcomes

  • Recommended Phase 2 Dose (Part 1) (Up to 24 months)
  • Objective Response Rate (Part 2) (Up to 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-09-14
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 165 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Iksuda Therapeutics Ltd.
Principal Investigators:
  • James O'Leary, MD (STUDY_DIRECTOR) - Iksuda Therapeutics
Contact Information
Study Contact:
David Browning
+1-615-975-7776
david.browning@iksuda.com
Monica Mita, MD
Hoag Memorial Hospital Presbyterian
Nancy Lin, MD
Dana Farber Cancer Institute
Interventions
  • Drug: IKS014 — IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.
Study Locations (13 sites)
Hoag Memorial Hospital Presbyterian, Newport Beach, California 92663 United States
Dana Farber Cancer Institute, Boston, Massachusetts 02215 United States
Tennessee Oncology, Nashville, Tennessee 37203 United States
START Dallas - Fort Worth, Fort Worth, Texas 76104 United States
Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit, Concord, New South Wales 2139 Australia
Macquarie University, Sydney, New South Wales 2109 Australia
Westmead Hospital, Westmead, New South Wales 2145 Australia
Peninsula & South Eastern Haematology and Oncology Group (PSEHOG), Frankston, Victoria 3199 Australia
Alfred Health, Melbourne, Victoria 3004 Australia
Linear Clinical Research, Nedlands, Western Australia 6009 Australia
Eligibility Criteria
Key Inclusion Criteria: * HER2 positive solid tumors with expression defined as IHC3+, IHC2+/ISH+, or low HER2 expression defined as IHC2+ (ISH-) or IHC1+ (ISH- /+ or untested). * Participants with HR positive BC must have received prior treatment with a CDK4/6 inhibitor, in countries where this is standard therapy. * Platelets ≥ 75,000 /mcL * Hemoglobin ≥ 9.0 g/dL * Absolute neutrophil count ≥ 1000/mcL * No administration of granulocyte colony-stimulating factor (G-CSF) is allowed within 2 weeks prior to first study drug administration * Creatinine clearance \> 45/mL/min (using the Cockcroft-Gault equation) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) ≤ 3 x institutional upper limit of normal (ULN) ≤ 5 x ULN if liver metastases present * Total bilirubin ≤ 1.5 x ULN if no liver metastases or \< 3 x ULN with Gilbert's Syndrome or liver metastases at baseline * Albumin \> 2.5 g/dL * Prothrombin time or international normalized ratio (INR) and either partial thromboplastin time (PTT) or activated (a) PTT ≤ 1.5 x ULN, ≤ 3 x institutional ULN if anticoagulated. * Must have adequate treatment washout period before trial treatment, defined as: Major surgery (≥ 4 weeks) and radiation therapy (≥ 3 weeks; in case of palliative radiation ≥ 2 weeks) * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (or equivalent Karnofsky PS) * Part 2 Dose Expansion Cohorts May Include: 1. Advanced or metastatic BC that is confirmed HER2-positive defined as IHC 3+ or IHC 2+ and evidence of HER2 amplification by ISH, as per ASCO-CAP and previously treated with at least two HER2 directed treatments. 2. Advanced or metastatic BC that has low HER2 expression defined as IHC2+ (ISH-) or IHC1+ (ISH-/+ or untested) and previously treated with at least 1 prior line of therapy which may include chemotherapy and/or a HER2 directed ADC. 3. Advanced or metastatic GC or GEJ cancer that is confirmed HER2-positive defined as IHC 3+ or IHC 2+ and evidence of HER2 amplification by ISH as per ASCO-CAP and previously treated with at least 1 prior line of therapy, which may include chemotherapy and/or a HER2 directed ADC. 4. Advanced or metastatic solid tumor that has been treated with standard of care therapy and is HER2 positive (HER2 IHC3+) as per ASCO-CAP or metastatic NSCLC (that has been treated with standard of care therapy) with a known activating HER2 (ERBB2) mutation. 5. Advanced or metastatic adenocarcinoma of the Esophagus that has been treated with at least one prior line of standard treatment, which may have included a HER2-directed therapy. The tumor must be HER2 positive defined either HER2 IHC3+ or HER2 IHC 2+/ISH+. Key Exclusion Criteria: * History of (noninfectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening. * Any clinically apparent ≥ Grade 2 pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e., pulmonary emboli within three months of the trial enrollment, severe asthma, severe chronic obstructive pulmonary disease \[COPD\], restrictive lung disease, pleural effusion, etc.), and any autoimmune, connective tissue or inflammatory disorders with potential pulmonary involvement (e.g., rheumatoid arthritis, Sjogren's, sarcoidosis), or prior pneumonectomy. * Current evidence of ≥ Grade 2 keratitis or other corneal abnormality. * Evidence of a clinically significant (≥ Grade 2) abnormality on slit-lamp examination or other clinically significant ophthalmologic finding, as determined by an ophthalmologist. * Evidence of clinically significant (≥ Grade 2) confluent superficial keratitis, a corneal epithelial defect, a corneal ulcer, or stromal opacity. * Participant must not use contact lenses while participating in this study. * Central nervous system metastatic disease unless treated with definitive local therapy (surgical resection, stereotactic radiotherapy, or whole brain radiotherapy) and participant is clinically, radiologically and neurologically stable for at least 4 weeks prior to the first dose of study drug not on steroid therapy or are on a stable or decreasing dose of steroids for at least 7 days prior to first dose of study drug. Prophylactic anticonvulsant medications are allowed. * Active second malignancy or history of another malignancy within the last 2 years with the exception of: * Treated, non-melanoma skin cancers * Treated carcinoma in situ (CIS) (e.g., breast, cervix) * Controlled, superficial carcinoma of the urinary bladder * T1a or b carcinoma of the prostate treated according to local standard of care, with prostate specific antigen (PSA) within normal limits (WNL) for the institution * Papillary thyroid carcinoma Stage I treated surgically for cure * Clinically significant cardiovascular disease or condition * Clinically significant liver disease * Any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever \> 38ºC within 2 weeks prior to first trial drug administration. * Any other serious, life-threatening, or unstable preexisting medical condition (aside from the underlying malignancy), including significant organ system dysfunction, or clinically significant laboratory abnormality(ies), which, in the opinion of the Investigator, would either compromise the participant's safety or interfere with obtaining informed consent, compliance with trial procedures, or evaluation of the safety of the trial drug.
Conditions Major Depressive Disorder
Phase PHASE2
Enrollment 106
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP 100mg BID + creatine 5g daily, 5-HTP 200mg BID + creatine 10g daily, vs double placebo, for 8 weeks. The ability of the interventions to affect biomarkers associated with depression will be assessed using brain phosphorus magnetic resonance spectroscopy, functional connectivity imaging, and plasma serotonin levels.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Low Dose 5-hydroxytryptophan — 5-hydroxytryptophan 100mg PO BID
  • Drug: High Dose 5-hydroxytryptophan — 5-hydroxytryptophan 200mg PO BID
  • Drug: Low Dose Creatine Monohydrate — Creatine monohydrate 5g PO qday
  • Drug: High Dose Creatine Monohydrate — Creatine monohydrate 10g PO qday
  • Drug: Placebo — Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)

Primary Outcomes

  • 17-Item Hamilton Depression Rating Scale (8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-09-28
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 106 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Utah
Contact Information
Study Contact:
Brent Kious, MD
8015851418
brent.kious@hsc.utah.edu
Hailey Nielson, MS
801-581-3475
hailey.nielson@utah.edu
Brent Kious
8015851418
brent.kious@hsc.utah.edu
University of Utah Department of Psychiatry
Interventions
  • Drug: Low Dose 5-hydroxytryptophan — 5-hydroxytryptophan 100mg PO BID
  • Drug: High Dose 5-hydroxytryptophan — 5-hydroxytryptophan 200mg PO BID
  • Drug: Low Dose Creatine Monohydrate — Creatine monohydrate 5g PO qday
  • Drug: High Dose Creatine Monohydrate — Creatine monohydrate 10g PO qday
  • Drug: Placebo — Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)
Study Locations (1 sites)
University of Utah Department of Psychiatry, Salt Lake City, Utah 84108 United States
Eligibility Criteria
Inclusion Criteria: * Adults age 18-65 years inclusive * Current diagnosis of MDD identified by the MINI (Mini Neuropsychiatric Interview) * Current HAM-D17 score of \>= 16 * Adequate adherence to any FDA approved SSRI or SNRI for at least 8 weeks * Right-handed * Residing at \> 4000 ft for at least 12 weeks Exclusion Criteria: * Any non-MDD and non-anxiety psychiatric diagnosis, as identified by the MINI * History of or current diagnosis of renal disease, such as chronic renal failure, acute renal failure or end stage renal disease * Current colitis or diverticulitis * History of or current pulmonary disease (except well controlled asthma) * Current smoking * History of cardiac disease or QTc \> 500ms * History of fibromyalgia or any rheumatological condition * History of or current seizure disorder * Current serious suicide risk identified by the Columbia Severity Suicide Rating Scale * Current treatment with an antipsychotic, mood stabilizer, or non-SSRI/SNRI antidepressant except for bupropion at FDA-approved doses or trazodone up to 200mg, or use of any supplements apart from standard multivitamins * Positive pregnancy test, pregnancy, failure to use adequate birth control method * Previous diagnosis of serotonin syndrome or evidence of serotonin syndrome * Pre-existing eosinophilia (absolute eosinophil count \> 500/uL) * Contraindications to MRI: ferromagnetic implants, implanted devices, claustrophobia
Conditions Music Therapy, Preterm Premature Rupture...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the effects of music therapy in the care of antepartum mothers admitted for long-term hospitalization due to the high-risk status of their pregnancy. The investigators speculate that mothers who receive music therapy will be more successful in forming positive coping habits, bonding with their infant, and increasing the length of incubation during their pregnancy. Furthermore, there is no research that correlates music therapy applied to stress reduction, increased coping, and increased caregiver-infant bonding prior to birth within one protocol. However, there is a significant amount of research supporting music therapy efficacy with neonatal intensive care unit infants and caregiver bonding post-partum as well as improved physiological signs of stress in infants in the post-partum period.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Music Therapy Intervention — Music Therapy Sessions. There will be 4 scheduled music therapy sessions, and a postpartum follow up.

Primary Outcomes

  • Measure the length of time from when the membranes prematurely rupture to delivery (30 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-05-15
Completion: 2026-03-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Christina Chianis Reed
Collaborators: The Methodist Hospital Research Institute
Principal Investigators:
  • Christina Reed, WHNP-BC (PRINCIPAL_INVESTIGATOR) - Baylor College of Medicine
Contact Information
Study Contact:
Christina C Reed, NP-BC
2817709027
Christina.reed@bcm.edu
Yamely Mendez Martinez, MD
832-826-7363
Yamely.mendezmartinez@bcm.edu
Christina C Reed, WHNP-BC
281-770-9027
christina.reed@bcm.edu
Texas Children's Pavilion for Women
Interventions
  • Behavioral: Music Therapy Intervention — Music Therapy Sessions. There will be 4 scheduled music therapy sessions, and a postpartum follow up.
Study Locations (1 sites)
Texas Children's Pavilion for Women, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: 1. Pregnant women between 18 and 64 years of age. 2. Singleton pregnancy. 3. Hospital admission due to a high risk of premature delivery. 4. Confirmed diagnosis of preterm premature rupture of membranes. 5. Length of stay in the hospital for 48 hours or more and stable for 48 hours or more. 6. Patients willing to listen to music. 7. Patients willing to participate throughout all the music therapy sessions and the postpartum follow-up visit. Exclusion Criteria: 1. Hospital length of stay of less than 48 hours. 2. Non-singleton pregnancy Gravidae with severe medical and or surgical complications during their hospital admission that prevents them from participating in Music Therapy sessions.
Conditions Alcohol Use Disorder, Severe
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to investigate the biological pathways underlying the beneficial effect of omega-3 polyunsaturated fatty acids (n-3 PUFA) on mental health in patients with alcohol use disorder. The main questions this study aims to answer are: * Can n-3 PUFA improve mood disorders (depression, anxiety), craving for alcohol, cognitive impairments and sociability disorders ? * Are the beneficial effects of n-3 PUFAs due to a modification of the gut microbiota and/or the inflammatory status? Participants will : * take a supplementation of omega-3 or placebo during 3 months * do a brain MRI * be interviewed for a dietary anamnesis * provide blood, stool and saliva samples * perform psychological tests and neuropsychological tasks Researchers will compare active comparator (omega-3) with placebo comparator (olive oil) to see if omega-3 can have a beneficial effect on AUD patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: Active Comparator: Omega-3 — It is a dietary supplement made of fish oil rich in n-3 PUFA.
  • Dietary Supplement: Placebo Comparator: olive oil — Refined olive oil is the usual placebo used in studies with n-3 PUFA.

Primary Outcomes

  • Change in depression (On day 2, day 19 and day 90)
  • Change in anxiety (On day 2, day 19 and day 90)
  • Change in fatigue (On day 2, day 19 and day 90)
  • Change in alcohol craving (On day 2, day 19 and day 90)
  • Change in impulsivity (On day 19 and day 90)
  • Change in social anxiety (On day 19 and day 90)
  • Change in trauma (On day 19)
  • Childhood trauma (On day 19)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-19
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Université Catholique de Louvain
Principal Investigators:
  • Philippe de Timary, MD, PhD (PRINCIPAL_INVESTIGATOR) - St Luc academic Hospital and Université Catholique de Louvain
  • Peter Starkel, MD, PhD (PRINCIPAL_INVESTIGATOR) - St Luc academic Hospital and Université Catholique de Louvain
Contact Information
Study Contact:
Sophie Leclercq, PhD
+3224361023
sophie.leclercq@uclouvain.be
Marie Mornard
marie.mornard@uclouvain.be
Sophie Leclercq
sophie.leclercq@uclouvain.be
Cliniques universitaires Saint Luc
Interventions
  • Dietary Supplement: Active Comparator: Omega-3 — It is a dietary supplement made of fish oil rich in n-3 PUFA.
  • Dietary Supplement: Placebo Comparator: olive oil — Refined olive oil is the usual placebo used in studies with n-3 PUFA.
Study Locations (1 sites)
Cliniques universitaires Saint Luc, Brussels, 1200 Belgium
Eligibility Criteria
Inclusion Criteria: * Diagnosis of alcohol use disorder (≥ 4 DSM-5 criteria) * Patient at the hospital for a 3 week alcohol withdrawal program * Gender : male and female * Age : between 18 and 70 years old * Language : french * Alcohol consumption less than 48 jours before admission Exclusion Criteria: * Presence of another addiction, except for smoking and cannabis use * Presence of a psychiatric comorbidity (axis 1 DSM-5) * Current or recent use (\< 2 months) of antibiotics, probiotics, fibre supplements * Current or recent (\< 2 months) use of omega-3 supplements * Current or recent (\< 2 months) use of oral anti-coagulants drugs * Current or recent (\< 2 months) double anti-platelet therapy * Coagulation disorders * Current or recent (\< 1 month) use of non-steroidal anti-inflammatory drugs and glucocorticoids * Morbid obesity : body mass index \> 35 kg.m-2 * Bariatric surgery * Type I diabetes and type II diabetes not stabilised (i.e. glycated haemoglobin \> 7.2 and unstable drug treatments) * Chronic inflammatory diseases * Cancer (less than 5 years before admission) * Presence of cirrhosis (Fibroscan® = F4 and echodoppler performed as part of clinical routine on patient admission) * Known allergy to fish and seafood * Any other comorbidity that would be a contraindication to the study in the judgement of the principal investigator

Gastroparesis Registry 4

NCT05846802
Recruiting
Conditions Gastroparesis, Gastroparesis Nondiabetic...
Phase Not Applicable
Enrollment 250
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The Gastroparesis Registry 4 (GpR4) is an observational study of patients with symptoms of gastroparesis (Gp) and functional dyspepsia (FD) with either delayed or normal gastric emptying. To better understand these disorders, this registry will capture demographic, clinical, physiological, questionnaire, and patient outcome data to characterize the patients and their clinical course. Participants will complete several questionnaires, complete a nutrient drink test and have a gastric emptying study.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Measure of symptom severity of gastroparesis and functional dyspepsia using the change in total score from the Patient Assessment of Upper Gastrointestinal Disorders Symptoms (PAGI SYM) from baseline to 48 weeks. (48 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-09-20
Completion: 2027-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins Bloomberg School of Public Health
Collaborators: Texas Tech University Health Sciences Center, El Paso, Temple University, University of Louisville, Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Massachusetts General Hospital, Wake Forest University
Principal Investigators:
  • Jay Pasricha, MD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
  • Henry Parkman, MD (PRINCIPAL_INVESTIGATOR) - Temple University
  • David Shade, JD (PRINCIPAL_INVESTIGATOR) - Johns Hopkins Bloomberg School of Public Health
Contact Information
Study Contact:
Laura Miriel
4435024165
lmiriel1@jhu.edu
Emily Mitchell, MS, MBA
esharke5@jhu.edu
Jay Pasricha, MD
pasricha.jay@mayo.org
Jay Pasricha
Interventions
N/A
Study Locations (6 sites)
Jay Pasricha, Scottsdale, Arizona 85259 United States
University of Louisville, Louisville, Kentucky 40202 United States
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Wake Forest University and Atrium Health Carolinas Medical Center, Charlotte, North Carolina 28202 United States
Temple University Hospital, Philadelphia, Pennsylvania 19140 United States
Texas Tech University Health Science Center (TTUHSC), El Paso, Texas 79905 United States
Eligibility Criteria
Inclusion Criteria: * Age at least 18 years at initial screening visit * Symptoms of Gp and/or FD of at least 12-weeks duration with varying degrees of nausea, vomiting, early satiety, postprandial fullness, abdominal pain, abdominal burning. Thus, patients can enter the GpR4 registry primarily with abdominal pain suggesting FD-Epigastric Pain Syndrome. * Successful completion of gastric emptying scintigraphy of solids using the 4-hour Egg Beaters® protocol (or equivalent generic liquid egg white meal) within the last 9 months * Negative upper endoscopy or upper radiographic GI series within 5 years of registration Exclusion Criteria: * Use of narcotic analgesics greater than three days per week * Presence of other conditions that could explain the patient's symptoms such as: * Pyloric or intestinal obstruction as evidenced by EGD, UGI, or Abdominal CT * Active inflammatory bowel disease * Known eosinophilic gastroenteritis or eosinophilic esophagitis * Primary neurological conditions that can cause nausea and vomiting such as increased intracranial pressure, space occupying or inflammatory/infectious lesions * Acute or chronic renal failure (serum creatinine \>3 mg/dL) and/or on hemodialysis or peritoneal dialysis * Acute liver failure or advanced liver disease (Child's B or C; a Child-Pugh-Turcotte (CPT) score of ≥7) * Pancreatic disorder if present on pancreatic imaging or pancreatic function testing * Prior gastric surgery including total or subtotal (near complete) gastric resection, esophagectomy, gastrojejunostomy, gastric bypass, gastric sleeve, pyloroplasty, pyloromyotomy, or any fundoplication (Nissen, Tor) * Any other condition, which in the opinion of the investigator, could explain the symptoms or interfere with study requirements * Females who are pregnant. A urine pregnancy test is routinely obtained on all females immediately prior to gastric emptying procedures. * Inability to comply with or complete the gastric emptying scintigraphy test (including allergy to eggs) * Inability to obtain informed consent
Conditions Unresectable Breast Cancer, Metastatic B...
Phase Not Applicable
Enrollment 2295
Locations 216 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Trastuzumab deruxtecan (T-DXd) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Based on the extended therapeutic indication of Trastuzumab deruxtecan (Enhertu®), a new patient population will be enrolled, comprising adult patients with unresectable or metastatic HR-positive, HER2-low, or HER2-(ultra)low breast cancer who have received at least one endocrine therapy in the metastatic setting and are not considered suitable for endocrine therapy as the next line of treatment.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Drug: Trastuzumab deruxtecan — This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice. Trastuzumab (T-DXd) to be administered according to the SmPC. Conventional therapy (eg. capecitabine, eribulin, gemcitabine, paclitaxel, nab paclitaxel) to be administered according to the SmPC.

Primary Outcomes

  • Real World Time to Next Treatment (rwTTNT1) in Participants With Unresectable and/or Metastatic Breast Cancer (Baseline up to approximately 37 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-10-24
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2295 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Principal Investigators:
  • Global Team Leader (STUDY_DIRECTOR) - Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Contact Information
Study Contact:
Contact for Clinical Trial Information
908-992-6400
CTRinfo@dsi.com
Principal Investigator
Medizinische Universität Graz
Principal Investigator
Klinikum Klagenfurt am Wörthersee
Interventions
  • Drug: Trastuzumab deruxtecan — This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice. Trastuzumab (T-DXd) to be administered according to the SmPC. Conventional therapy (eg. capecitabine, eribulin, gemcitabine, paclitaxel, nab paclitaxel) to be administered according to the SmPC.
Study Locations (216 sites)
Medizinische Universität Graz, Graz, 8036 Austria
Medizinische Universität Graz, Graz, 8036 Austria
Medizinische Universität Innsbruck, Innsbruck, 6020 Austria
Klinikum Klagenfurt am Wörthersee, Klagenfurt, 9020 Austria
LKH Hochsteiermark-Leoben, Leoben, 8700 Austria
Ordensklinikum Linz GmbH Barmherzige Schwestern, Linz, 4010 Austria
Interne II, LKH Feldkirch, Rankweil, 6830 Austria
KH der Barmherzigen Brüder Salzburg, Salzburg, 5010 Austria
Uniklinikum Salzburg, Salzburg, 5020 Austria
Medical University of Vienna, Vienna, 1090 Austria
Eligibility Criteria
Inclusion Criteria: Study Group 1 and Study Group 2 * Adult patient (age ≥ 18 years) with histological or cytological confirmed diagnosis of unresectable and/or mBC * Decision to newly initiate therapy of T-DXd or conventional chemotherapy according to the physicians choice per SmPC * Written and signed Informed Consent to participate in the study Study Group 1 * Documented HER2-low status (IHC1+, IHC2+/ISH-) * Patients who have received prior chemotherapy in the metastatic setting or * Patients who have developed disease recurrence during or within 6 months of completing adjuvant chemotherapy Study Group 2: * Documented HR+ status * Documented HER2-low status (IHC1+ or IHC2+/ISH-) or HER2-ultralow (defined as IHC 0 with membrane staining \[IHC \> 0 to \<1+\]) status * Patients who have received at least one endocrine therapy in the metastatic setting * Patients who have NOT received prior chemotherapy in the metastatic setting Exclusion Criteria: Study Group 1 and Study Group 2 * Pregnancy or breastfeeding * Patients who at time of data collection for this study are participating in or have participated in an interventional study that remains blinded. No other specific exclusion criteria are defined, as patients will be treated according to the proposed indication statements in the SmPC.